Blurbs

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL) and Haemonetics (HAE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals (MDGLResearch Report) and Haemonetics (HAEResearch Report).

Madrigal Pharmaceuticals (MDGL)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals today and set a price target of $182.00. The company’s shares closed last Monday at $64.62.

According to TipRanks.com, Wolleben is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.3% and a 31.1% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Protagonist Therapeutics.

Currently, the analyst consensus on Madrigal Pharmaceuticals is a Strong Buy with an average price target of $148.86, a 122.6% upside from current levels. In a report issued on November 3, SVB Securities also maintained a Buy rating on the stock with a $145.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Haemonetics (HAE)

In a report released today, Michael Matson from Needham maintained a Hold rating on Haemonetics. The company’s shares closed last Monday at $82.42, close to its 52-week high of $85.97.

According to TipRanks.com, Matson is a 1-star analyst with an average return of -1.4% and a 42.4% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Haemonetics has an analyst consensus of Moderate Buy, with a price target consensus of $86.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MDGL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More